The aim of our analysis was to describe the prognostic significance of a novel high-sensitivity cardiac troponin I assay (Atellica® IM high-sensitivity troponin I, Siemens Healthineers) in a cohort of patients with stable systolic chronic heart failure (reduced or mid-range ejection fraction) and evaluate its contribution to NT-proBNP levels and clinical parameters. This evidence concerns the gene NPPB and congestive heart failure.